Counterpoint Mutual Funds LLC Invests $565,000 in AxoGen, Inc. (NASDAQ:AXGN)

Counterpoint Mutual Funds LLC purchased a new position in AxoGen, Inc. (NASDAQ:AXGN) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 34,275 shares of the medical equipment provider’s stock, valued at approximately $565,000. Counterpoint Mutual Funds LLC owned about 0.08% of AxoGen at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new position in shares of AxoGen in the 4th quarter worth about $4,552,000. Charles Schwab Investment Management Inc. increased its holdings in AxoGen by 14.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 416,610 shares of the medical equipment provider’s stock worth $6,866,000 after buying an additional 52,846 shares in the last quarter. US Bancorp DE bought a new stake in AxoGen in the 4th quarter worth about $30,000. Y Intercept Hong Kong Ltd bought a new stake in AxoGen in the 4th quarter worth about $235,000. Finally, Bradley Foster & Sargent Inc. CT increased its holdings in AxoGen by 3.7% in the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 84,153 shares of the medical equipment provider’s stock worth $1,387,000 after buying an additional 2,989 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

AXGN has been the subject of several research analyst reports. Canaccord Genuity Group lifted their price objective on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $24.00 price objective on shares of AxoGen in a report on Wednesday, March 5th. Finally, Lake Street Capital began coverage on AxoGen in a report on Monday. They issued a “buy” rating and a $30.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $22.60.

AxoGen Price Performance

Shares of AxoGen stock opened at $18.28 on Tuesday. The stock has a market cap of $810.61 million, a P/E ratio of -57.13 and a beta of 1.02. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The stock’s fifty day moving average is $18.08 and its 200 day moving average is $15.54. AxoGen, Inc. has a one year low of $5.55 and a one year high of $21.00.

Insider Activity at AxoGen

In related news, Director Amy Mcbride Wendell sold 5,000 shares of AxoGen stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the director now directly owns 97,899 shares in the company, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.00% of the stock is owned by company insiders.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.